Garivulimab (BGB-A333) is a humanized IgG1 variant monoclonal antibody targeting programmed cell death ligand 1 (PD-L1). By specifically binding to PD-L1 on the surface of tumor or immune cells, it effectively blocks its interaction with the PD-1 receptor on T cells. This blockade reverses T-cell inactivation (exhaustion), promotes T-cell expansion and activation, and inhibits CD8+ T-cell apoptosis. By restoring the immune system's ability to recognize and eliminate PD-L1-expressing tumors, Garivulimab demonstrates significant anti-tumor potential in research involving various advanced solid tumors.